Section 2: Selection, Procurement and Distribution
2SPD-011
TRANS-INTERFACE GAIN SHARE PROGRAMME FOR BIOSSIMILAR INFLIXIMAB (submitted in 2019)
2SPD-010
ECONOMIC IMPACT OF SWITCHING THE ADMINISTRATION ROUTE OF TOCILIZUMAB IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (submitted in 2019)
2SPD-009
COST MINIMISATION STUDY OF THE BIOLOGICAL TREATMENT OF INFLAMMATORY BOWEL DISEASE: USTEKINUMAB VERSUS VEDOLIZUMAB (submitted in 2019)
2SPD-008
IMPACT OF FRENCH EXPERIMENT FOR INCENTIVISING ETANERCEPT BIOSIMILAR USE AFTER 10 MONTHS (submitted in 2019)
2SPD-007
OUT OF SUPPLY OF CHEMOTHERAPY INJECTABLE MEDICINES OVER 9 MONTHS: PATIENT IMPACT (submitted in 2019)
2SPD-006
ASSESSMENT OF REGORAFENIB, RAMUCIRUMAB AND CABOZANTINIB AS SECONDLINE THERAPY IN HEPATOCARCINOMA AND ALFA-FETOPROTEIN VALUE ≥400 NG/ML (submitted in 2019)
2SPD-005
ECONOMIC ANALYSIS OF OSIMERTINIB IN PREVIOUSLY UNTREATED EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (submitted in 2019)
2SPD-004
EFFICIENCY OF PRECISION DOSING WITH INTRAVENOUS IMMUNOGLOBULINS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES (submitted in 2019)
2SPD-003
ECONOMIC IMPACT OF THE INTRODUCTION OF LAMIVUDINE PLUS DOLUTEGRAVIR BITHERAPY IN HIV NAIVE PATIENTS (submitted in 2019)
2SPD-002
IMPROVEMENT IN AN ANTIMICROBIAL STEWARDSHIP PROGRAMME AFTER IMPLEMENTING A SCREENING ALERT SYSTEM (submitted in 2019)
2SPD-001
IMPLEMENTATION OF HOME DELIVERY AND TELEPHARMACY SYSTEMS IN A THIRD LEVEL HOSPITAL (submitted in 2019)
2SPD-041
DRUG SHORTAGES ANALYSIS FROM AN ITALIAN HOSPITAL PHARMACY PERSPECTIVE
2SPD-040
IS PNEUMATIC TUBE DELIVERY SAFE FOR MEDICINES?
2SPD-039
MEDICINE SHORTAGES IN A GENERAL COUNTY HOSPITAL: EVALUATION AND ESSENTIAL QUALITY
2SPD-038
HOW LONG DO HOSPITAL PHARMACISTS SPEND IN MANAGING MEDICINES SHORTAGES?
